M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer

Phase 2

Withdrawn

Conditions: ATM Gene Mutation
Deleterious BRCA1 Gene Mutation
Deleterious BRCA2 Gene Mutation
Homologous Recombination Deficiency
Pancreatic Ductal Adenocarcinoma
Stage II Pancreatic Cancer AJCC v8
Stage IIA Pancreatic Cancer AJCC v8
Stage IIB Pancreatic Cancer AJCC v8
Stage III Pancreatic Cancer AJCC v8
Stage IV Pancreatic Cancer AJCC v8

Interventions: Drug: Epacadostat
Biological: Pembrolizumab

First Posted Date: 2018-02-14

Last Posted Date: 2019-05-30

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT03432676

Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors

Phase 1

Completed

Conditions: Recurrent Malignant Solid Neoplasm
Refractory Malignant Solid Neoplasm

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Drug: Sapanisertib

First Posted Date: 2018-02-13

Last Posted Date: 2022-06-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 35

Registration Number: NCT03430882

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

An Early Stress-Reduction Intervention in Patients With Newly Diagnosed Breast Cancer

Not Applicable

Active, not recruiting

Conditions: Malignant Neoplasm of Breast

Interventions: Behavioral: Mind-Body Exercises
Behavioral: Questionnaires

First Posted Date: 2018-02-12

Last Posted Date: 2025-05-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 62

Registration Number: NCT03429907

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer

Phase 2

Completed

Conditions: Malignant Neoplasms of Digestive Organs
Colorectal Cancer
Colon Cancer

Interventions: Drug: Durvalumab
Drug: Trametinib

First Posted Date: 2018-02-09

Last Posted Date: 2023-06-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 29

Registration Number: NCT03428126

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

Early Phase 1

Completed

Conditions: Primary Myelofibrosis
Secondary Myelofibrosis

Interventions: Drug: Cyclophosphamide
Biological: Filgrastim
Drug: Fludarabine Phosphate
Procedure: Hematopoietic Cell Transplantation
Drug: Melphalan
Drug: Mycophenolate Mofetil
Drug: Tacrolimus
Radiation: Total-Body Irradiation

First Posted Date: 2018-02-08

Last Posted Date: 2020-10-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT03426969

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Phase 1

Recruiting

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Immunocompromised

Interventions: Biological: Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes

First Posted Date: 2018-02-07

Last Posted Date: 2025-03-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 16

Registration Number: NCT03425526

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

Phase 1

Recruiting

Conditions: Recurrent Malignant Skin Neoplasm
Recurrent Cutaneous Melanoma
Recurrent Malignant Female Reproductive System Neoplasm
Refractory Malignant Male Reproductive System Neoplasm
Refractory Malignant Oral Neoplasm
Recurrent Malignant Pharyngeal Neoplasm
Recurrent Malignant Soft Tissue Neoplasm
Recurrent Malignant Urinary System Neoplasm
Refractory Cutaneous Melanoma
Refractory Malignant Bone Neoplasm

Interventions: Biological: Cord Blood-derived Expanded Allogeneic Natural Killer Cells
Drug: Cyclophosphamide
Drug: Etoposide

First Posted Date: 2018-02-05

Last Posted Date: 2025-02-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 38

Registration Number: NCT03420963

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Continuous Positive Airway Pressure Device or Deep Inspiration Breath Hold in Reducing Tumor Motion in Patients Undergoing Stereotactic Body Radiation Therapy for Lung Cancer

Phase 1

Active, not recruiting

Conditions: Lung Carcinoma
Metastatic Malignant Neoplasm in the Lung
Malignant Respiratory Tract Neoplasm

Interventions: Device: Biphasic Positive Airway Pressure
Procedure: Computed Tomography
Procedure: Continuous Positive Airway Pressure
Procedure: Deep Inspiration Breath Hold
Radiation: Radiation Therapy Treatment Planning and Simulation
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2018-02-05

Last Posted Date: 2025-01-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT03422302

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation

Phase 1

Completed

Conditions: Plasma Cell Myeloma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Biological: Filgrastim-sndz
Drug: Melphalan Hydrochloride

First Posted Date: 2018-01-31

Last Posted Date: 2025-05-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 62

Registration Number: NCT03417284

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy

Phase 2

Active, not recruiting

Conditions: Prostate Adenocarcinoma
Stage IIB Prostate Cancer AJCC v8

Interventions: Drug: Apalutamide
Other: Quality-of-Life Assessment
Procedure: Radical Prostatectomy

First Posted Date: 2018-01-26

Last Posted Date: 2025-02-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT03412396

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy